Grants per year
Personal profile
Research Interests
My research interest is in the relationship of clinical outcomes in Hypertrophic cardiomyopathy patients with their cardiac imaging findings. My clinical interests include, the care of patients with hypertrophic cardiomyopathy, family history of sudden cardiac death, left ventricular hypertrophy, valvular heart disease, coronary artery disease and preoperative cardiac evaluation.
Certifications and Licenses
| Cardiovascular Disease |
Training Experience
| 1997 | Residency, Detroit Medical Center |
| 2001 | Fellowship, Northwestern University, McGaw Medical Center (Northwestern Memorial Hospital) |
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
MD, Medicine, University College Galway
… → 1995
Research interests keywords
- Cardiomyopathy
- Cardiovascular Imaging
- Heart Disease
- Hypertrophic Cardiomyopathy/Myectomy
- Sudden Cardiac Death
- Valvular Disease
Fingerprint
Dive into the research topics where Lubna Choudhury is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Prot #LX4211.1-314-HCM: A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Multicenter Study to Evaluate the Efficacy and Safety of SOtaglifloziN in symptomATic obstructive And non-obstructive Hypertrophic CardioMyopathy (SONATA-HCM)
Choudhury, L. (PD/PI)
Fortrea, Inc., Lexicon Pharmaceuticals, Inc.
12/20/24 → 12/20/27
Project: Research project
-
Prot #CY 6033: A Phase 3, Multi‐Center, Randomized, Double‐blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Placebo in Adults with Symptomatic Non‐Obstructive Hypertrophic Cardiomyopathy
Choudhury, L. (PD/PI)
ICON Clinical Research, LLC, Cytokinetics, Inc.
10/5/23 → 10/5/26
Project: Research project
-
Prot #CY 6032: A Phase 3, Multi‐Center, Randomized, Double‐Blind Trial to Evaluate the Efficacy and Safety of Aficamten Compared to Metoprolol in Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy
Choudhury, L. (PD/PI)
Fortrea, Inc., Cytokinetics, Inc.
8/3/23 → 8/3/26
Project: Research project
-
Prot#IMB-101-007: A Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Safety, Tolerability, and Efficacy of IMB-1018972 in Patients with Non-obstructive Hypertrophic Cardiomyopathy
Choudhury, L. (PD/PI)
Cardiovascular Clinical Science Foundation, Imbria Pharmaceuticals, Inc.
8/24/21 → 8/23/26
Project: Research project
-
Protocol # CY6022: An Open Label Study of CK-3773274 for Patients with Symptomatic Hypertrophic Cardiomyopathy (HCM) and Left Ventricular Outflow Tract Obstruction
Choudhury, L. (PD/PI), Kansal, P. (Co-Investigator), Narang, A. (Co-Investigator) & Puthumana, J. J. (Co-Investigator)
7/28/21 → 7/28/27
Project: Research project
-
Comparison of Alcohol Septal Ablation With Mavacamten in Obstructive Hypertrophic Cardiomyopathy
Samhan, A., Saleh, D., Kim, E. Y., Hu, M., Mueller, K., Garza, A., Schormann, E., Bindra, P., Cheema, B., Fullenkamp, D. E., Baldridge, A. S., Puthumana, J. J., Flaherty, J. D. & Choudhury, L., Mar 15 2025, In: American Journal of Cardiology. 239, p. 51-56 6 p.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Large-scale genome-wide association analyses identify novel genetic loci and mechanisms in hypertrophic cardiomyopathy
Hypergenes InterOmics Collaborators & HCMR Investigators, Mar 2025, In: Nature Genetics. 57, 3, p. 530-538 9 p., 1826.Research output: Contribution to journal › Article › peer-review
1 Scopus citations -
Valsartan and Cardiac Remodeling in Early-Stage Hypertrophic Cardiomyopathy: The VANISH Randomized Clinical Trial Cardiac Magnetic Resonance Substudy
The Valsartan for Attenuating Disease Evolution in Early Sarcomeric Hypertrophic Cardiomyopathy (VANISH) Investigators, 2025, (Accepted/In press) In: JAMA cardiology.Research output: Contribution to journal › Article › peer-review
-
Aficamten for Symptomatic Obstructive Hypertrophic Cardiomyopathy
Maron, M. S., Masri, A., Nassif, M. E., Barriales-Villa, R., Arad, M., Cardim, N., Choudhury, L., Claggett, B., Coats, C. J., Düngen, H. D., Garcia-Pavia, P., Hagège, A. A., Januzzi, J. L., Lee, M. M. Y., Lewis, G. D., Ma, C. S., Michels, M., Olivotto, I., Oreziak, A. & Owens, A. T. & 13 others, , May 30 2024, In: New England Journal of Medicine. 390, 20, p. 1849-1861 13 p.Research output: Contribution to journal › Article › peer-review
105 Scopus citations -
Dosing and Safety Profile of Aficamten in Symptomatic Obstructive Hypertrophic Cardiomyopathy: Results From SEQUOIA-HCM
on behalf of the SEQUOIA-HCM Investigators, Aug 6 2024, In: Journal of the American Heart Association. 13, 15, e035993.Research output: Contribution to journal › Article › peer-review
Open Access7 Scopus citations